Click here for slides on this topic


Diabetes Prevention Program (DPP)

A randomized, controlled trial that investigated whether lifestyle changes or metformin therapy compared with placebo could prevent or delay the onset of type 2 diabetes among patients with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). Over 2.8 years of follow-up versus placebo, lifestyle intervention reduced the incidence of type 2 diabetes by 58%; metformin reduced the incidence of type 2 diabetes by 31%.
The following content matched the glossary term: Diabetes Prevention Program (DPP)

NDEI.org Expert Commentary on Type 2 Diabetes Prevention in SEQUEL from Vivian Fonseca

Top

NDEI Education Council Member Vivian A. Fonseca, MD, comments on type 2 diabetes prevention in a substudy of SEQUEL: “Weight loss alone may be an option to prevent type 2 diabetes”

Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus

Top

Patil HR, Al Badarin FJ, Al Shami HA, et al. Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus. Am J Cardiol. 2012;110:826-833. This meta-analysis from Patil and colleagues provides insights into the effects of DPP-4 inhibitors on cardiovascular (CV) events, and is the first adequately powered study that shows a class-wide effect for DPP-4 inhibitors in decreasing CV event risk over long-term treatment (≥24 weeks).

Efficacy & safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 wks in metformin-treated patients

Top

Pratley RE, Nauck MA, Bailey T, et al. Efficacy and safety of switching from the DPP-4 inhibitor sitagliptin to the human GLP-1 analog liraglutide after 52 weeks in metformin-treated patients with type 2 diabetes: a randomized, open-label trial. Diabetes Care. 2012;35(10):1986-1993. In 2011, Pratley and colleagues reported 52-week data from a trial that explored treatment with the DPP-4 inhibitor, sitagliptin, and the GLP-1 receptor agonist, liraglutide, among subjects with type 2 diabetes and A1C 7.5%–10%.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin

Top

Gallwitz B, Rosenstock J, Rauch T, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012;380(9840):475-483. A recent position statement from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) cites metformin as the optimal first-line drug for diabetes treatment. However, the statement acknowledges that limited data exist regarding treatments to be used beyond metformin.

Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study

Top

Lorenzo C, Lee R, Haffner SM. Impaired Glucose Tolerance and Obesity as Effect Modifiers of Ethnic Disparities of the Progression to Diabetes: The San Antonio Heart Study. Diabetes Care. 2012 Aug 24. Epub ahead of print. The Diabetes Prevention Program (DPP) reported no racial/ethnic differences in the incidence of diabetes in individuals with impaired glucose tolerance (IGT). Therefore, it has been hypothesized that factors associated with racial/ethnic disparities act prior to the development of IGT.

NDEI.org Expert Commentary on EUREXA Trial Burton Sobel, MD

Top

NDEI.org expert commentary on European Exenatide (EUREXA) trial from Burton Sobel, MD

Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes

Top

Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Meta-analysis: DPP-4 Inhibitors for Type 2 Diabetes. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369. Karagiannis and colleagues conducted a systematic review and meta-analysis of 27 studies to evaluate the efficacy of DPP-4 inhibitors for treatment of type 2 diabetes when compared with other antihyperglycemic therapies.

EASIE: Insulin Glargine vs Sitagliptin in Insulin-naïve Patients with Type 2 Diabetes Uncontrolled on Metformin

Top

Continuous coverage of ADA 2012. Aschner P, Chan J, Owens DR, et al; on behalf of the EASIE investigators. EASIE: Insulin Glargine vs Sitagliptin in Insulin-naïve Patients with Type 2 Diabetes Uncontrolled on Metformin. Lancet. 2012;379(9833):2262-2269. The Evaluation of insulin glargine versus Sitagliptin in Insulin-naïve patients (EASIE) trial is a multicenter, randomized, parallel, open-label trial that examined the efficacy, safety, and tolerability of a basal insulin, insulin glargine, vs a DPP-4 inhibitor, sitagliptin, among insulin-naïve patients with type 2 diabetes that was uncontrolled on metformin.

DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction

Top

Continuous coverage of ADA 2012. Perreault L, Pan Q, Mather KJ, et al; for the Diabetes Prevention Program Research Group. DPPOS: Effect of Regression from Prediabetes to NGR on Long-term Diabetes Risk Reduction. Lancet. 2012;379(9833):2243-2251. This report sought to quantify and predict diabetes risk reduction during the long-term follow-up to the Diabetes Prevention Program (DPP), the Diabetes Prevention Program Outcomes Study (DPPOS).

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

1 2 3 4 5 6 Next 

Slide Library Results

Search Results for: Diabetes Prevention Program (DPP) Slides Found: 22
Risk of Type 2 Diabetes in People With Impaired Glucose Tolerance
Type 2 Diabetes Prevention Studies
US DPP Incidence of Type 2 Diabetes With Different Interventions
Finnish Diabetes Prevention Study: Sustained Benefit of Lifestyle Intervention
DPP and DPPOS: Timeline
DPP: A Look Back
DPPOS Bridge: Year 4
DPPOS Maintenance: Years 5-10
Long-Term Use of Metformin in DPPOS
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Medication Adherence
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Weight Loss
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Waist Circumference
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Achievement of ≥5% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase—Achievement of ≥10% Loss of Body Weight
Long-Term Use of Metformin in DPPOS: Results from the DPP Double-Blind Phase— Effect of Adherence on Body Weight, Waist Circumference
Long-Term Use of Metformin in DPPOS: Results Including DPPOS Open-Label Treatment—Metformin Adherence
Long-Term Use of Metformin in DPPOS: Results During DPP—Safety & Tolerability
Long-Term Use of Metformin in DPPOS: Results During DPP—Average Hemoglobin, Hematocrit Levels Over Time
DPPOS Substudy: Effect of Regression from Prediabetes to NGR on Diabetes Risk
DPPOS Substudy: NGR Status and Risk Reduction
DPPOS Substudy: NGR Predictors During DPPOS
DPPOS Substudy: Additional Outcomes